Can CereVasc’s $85m raise move hydrocephalus treatment beyond traditional shunt surgery?
CereVasc’s $85m raise backs eShunt, a minimally invasive hydrocephalus device. The STRIDE trial now carries the real test.
CereVasc’s $85m raise backs eShunt, a minimally invasive hydrocephalus device. The STRIDE trial now carries the real test.
BrainSpace, a U.S.-based medical technology company, has received 510(k) clearance from the U.S. Food and Drug Administration for Intellidrop, a fully automated cerebrospinal fluid (CSF) drainage and intracranial pressure (ICP) monitoring system. The cleared indication covers ventricular or lumbar use in patients requiring external CSF drainage and continuous pressure monitoring—making it potentially relevant across a